B T Li1, F Janku2, B Jung3, C Hou3, K Madwani2, R Alden4, P Razavi5, J S Reis-Filho6, R Shen7, J M Isbell8, A W Blocker9, N Eattock3, S Gnerre3, R V Satya3, H Xu3, C Zhao10, M P Hall9, Y Hu4, A J Sehnert3, D Brown6, M Ladanyi6, C M Rudin5, N Hunkapiller9, N Feeney11, G B Mills2, C P Paweletz11, P A Janne12, D B Solit13, G J Riely5, A Aravanis3, G R Oxnard4. 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York. Electronic address: lib1@mskcc.org. 2. Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston. 3. Illumina, Inc., San Francisco. 4. Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston. 5. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York. 6. Departments of Pathology. 7. Epidemiology and Biostatistics. 8. Surgery, Memorial Sloan Kettering Cancer Center, New York. 9. GRAIL, Inc., Menlo Park. 10. Illumina, Inc., San Diego. 11. Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston. 12. Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston. 13. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Cancer Center, New York, USA.
Abstract
BACKGROUND: Noninvasive genotyping using plasma cell-free DNA (cfDNA) has the potential to obviate the need for some invasive biopsies in cancer patients while also elucidating disease heterogeneity. We sought to develop an ultra-deep plasma next-generation sequencing (NGS) assay for patients with non-small-cell lung cancers (NSCLC) that could detect targetable oncogenic drivers and resistance mutations in patients where tissue biopsy failed to identify an actionable alteration. PATIENTS AND METHODS: Plasma was prospectively collected from patients with advanced, progressive NSCLC. We carried out ultra-deep NGS using cfDNA extracted from plasma and matched white blood cells using a hybrid capture panel covering 37 lung cancer-related genes sequenced to 50 000× raw target coverage filtering somatic mutations attributable to clonal hematopoiesis. Clinical sensitivity and specificity for plasma detection of known oncogenic drivers were calculated and compared with tissue genotyping results. Orthogonal ddPCR validation was carried out in a subset of cases. RESULTS: In 127 assessable patients, plasma NGS detected driver mutations with variant allele fractions ranging from 0.14% to 52%. Plasma ddPCR for EGFR or KRAS mutations revealed findings nearly identical to those of plasma NGS in 21 of 22 patients, with high concordance of variant allele fraction (r = 0.98). Blinded to tissue genotype, plasma NGS sensitivity for de novo plasma detection of known oncogenic drivers was 75% (68/91). Specificity of plasma NGS in those who were driver-negative by tissue NGS was 100% (19/19). In 17 patients with tumor tissue deemed insufficient for genotyping, plasma NGS identified four KRAS mutations. In 23 EGFR mutant cases with acquired resistance to targeted therapy, plasma NGS detected potential resistance mechanisms, including EGFR T790M and C797S mutations and ERBB2 amplification. CONCLUSIONS: Ultra-deep plasma NGS with clonal hematopoiesis filtering resulted in de novo detection of targetable oncogenic drivers and resistance mechanisms in patients with NSCLC, including when tissue biopsy was inadequate for genotyping.
BACKGROUND: Noninvasive genotyping using plasma cell-free DNA (cfDNA) has the potential to obviate the need for some invasive biopsies in cancerpatients while also elucidating disease heterogeneity. We sought to develop an ultra-deep plasma next-generation sequencing (NGS) assay for patients with non-small-cell lung cancers (NSCLC) that could detect targetable oncogenic drivers and resistance mutations in patients where tissue biopsy failed to identify an actionable alteration. PATIENTS AND METHODS: Plasma was prospectively collected from patients with advanced, progressive NSCLC. We carried out ultra-deep NGS using cfDNA extracted from plasma and matched white blood cells using a hybrid capture panel covering 37 lung cancer-related genes sequenced to 50 000× raw target coverage filtering somatic mutations attributable to clonal hematopoiesis. Clinical sensitivity and specificity for plasma detection of known oncogenic drivers were calculated and compared with tissue genotyping results. Orthogonal ddPCR validation was carried out in a subset of cases. RESULTS: In 127 assessable patients, plasma NGS detected driver mutations with variant allele fractions ranging from 0.14% to 52%. Plasma ddPCR for EGFR or KRAS mutations revealed findings nearly identical to those of plasma NGS in 21 of 22 patients, with high concordance of variant allele fraction (r = 0.98). Blinded to tissue genotype, plasma NGS sensitivity for de novo plasma detection of known oncogenic drivers was 75% (68/91). Specificity of plasma NGS in those who were driver-negative by tissue NGS was 100% (19/19). In 17 patients with tumor tissue deemed insufficient for genotyping, plasma NGS identified four KRAS mutations. In 23 EGFR mutant cases with acquired resistance to targeted therapy, plasma NGS detected potential resistance mechanisms, including EGFRT790M and C797S mutations and ERBB2 amplification. CONCLUSIONS: Ultra-deep plasma NGS with clonal hematopoiesis filtering resulted in de novo detection of targetable oncogenic drivers and resistance mechanisms in patients with NSCLC, including when tissue biopsy was inadequate for genotyping.
Authors: David S Ettinger; Douglas E Wood; Dara L Aisner; Wallace Akerley; Jessica Bauman; Lucian R Chirieac; Thomas A D'Amico; Malcolm M DeCamp; Thomas J Dilling; Michael Dobelbower; Robert C Doebele; Ramaswamy Govindan; Matthew A Gubens; Mark Hennon; Leora Horn; Ritsuko Komaki; Rudy P Lackner; Michael Lanuti; Ticiana A Leal; Leah J Leisch; Rogerio Lilenbaum; Jules Lin; Billy W Loo; Renato Martins; Gregory A Otterson; Karen Reckamp; Gregory J Riely; Steven E Schild; Theresa A Shapiro; James Stevenson; Scott J Swanson; Kurt Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2017-04 Impact factor: 11.908
Authors: Adrian G Sacher; Cloud Paweletz; Suzanne E Dahlberg; Ryan S Alden; Allison O'Connell; Nora Feeney; Stacy L Mach; Pasi A Jänne; Geoffrey R Oxnard Journal: JAMA Oncol Date: 2016-08-01 Impact factor: 31.777
Authors: Joshua K Sabari; Michael Offin; Dennis Stephens; Andy Ni; Adrian Lee; Nick Pavlakis; Stephen Clarke; Connie I Diakos; Sutirtha Datta; Nidhi Tandon; Andres Martinez; Mackenzie L Myers; Alex Makhnin; Ysleni Leger; Helena A Yu; Paul K Paik; Jamie E Chaft; Mark G Kris; Jeong O Jeon; Laetitia A Borsu; Marc Ladanyi; Maria E Arcila; Jennifer Hernandez; Samantha Henderson; Tristan Shaffer; Kavita Garg; Dan DiPasquo; Christopher K Raymond; Lee P Lim; Mark Li; Matthew D Hellmann; Alexander Drilon; Gregory J Riely; Valerie W Rusch; David R Jones; Andreas Rimner; Charles M Rudin; James M Isbell; Bob T Li Journal: J Natl Cancer Inst Date: 2019-06-01 Impact factor: 13.506
Authors: Lynette M Sholl; Dara L Aisner; Marileila Varella-Garcia; Lynne D Berry; Dora Dias-Santagata; Ignacio I Wistuba; Heidi Chen; Junya Fujimoto; Kelly Kugler; Wilbur A Franklin; A John Iafrate; Marc Ladanyi; Mark G Kris; Bruce E Johnson; Paul A Bunn; John D Minna; David J Kwiatkowski Journal: J Thorac Oncol Date: 2015-05 Impact factor: 15.609
Authors: Chetan Bettegowda; Mark Sausen; Rebecca J Leary; Isaac Kinde; Yuxuan Wang; Nishant Agrawal; Bjarne R Bartlett; Hao Wang; Brandon Luber; Rhoda M Alani; Emmanuel S Antonarakis; Nilofer S Azad; Alberto Bardelli; Henry Brem; John L Cameron; Clarence C Lee; Leslie A Fecher; Gary L Gallia; Peter Gibbs; Dung Le; Robert L Giuntoli; Michael Goggins; Michael D Hogarty; Matthias Holdhoff; Seung-Mo Hong; Yuchen Jiao; Hartmut H Juhl; Jenny J Kim; Giulia Siravegna; Daniel A Laheru; Calogero Lauricella; Michael Lim; Evan J Lipson; Suely Kazue Nagahashi Marie; George J Netto; Kelly S Oliner; Alessandro Olivi; Louise Olsson; Gregory J Riggins; Andrea Sartore-Bianchi; Kerstin Schmidt; le-Ming Shih; Sueli Mieko Oba-Shinjo; Salvatore Siena; Dan Theodorescu; Jeanne Tie; Timothy T Harkins; Silvio Veronese; Tian-Li Wang; Jon D Weingart; Christopher L Wolfgang; Laura D Wood; Dongmei Xing; Ralph H Hruban; Jian Wu; Peter J Allen; C Max Schmidt; Michael A Choti; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Luis A Diaz Journal: Sci Transl Med Date: 2014-02-19 Impact factor: 17.956
Authors: Geoffrey R Oxnard; Cloud P Paweletz; Yanan Kuang; Stacy L Mach; Allison O'Connell; Melissa M Messineo; Jason J Luke; Mohit Butaney; Paul Kirschmeier; David M Jackman; Pasi A Jänne Journal: Clin Cancer Res Date: 2014-01-15 Impact factor: 12.531
Authors: Steven M Teutsch; Linda A Bradley; Glenn E Palomaki; James E Haddow; Margaret Piper; Ned Calonge; W David Dotson; Michael P Douglas; Alfred O Berg Journal: Genet Med Date: 2009-01 Impact factor: 8.822
Authors: Ahmet Zehir; Ryma Benayed; Ronak H Shah; Aijazuddin Syed; Sumit Middha; Hyunjae R Kim; Preethi Srinivasan; Jianjiong Gao; Debyani Chakravarty; Sean M Devlin; Matthew D Hellmann; David A Barron; Alison M Schram; Meera Hameed; Snjezana Dogan; Dara S Ross; Jaclyn F Hechtman; Deborah F DeLair; JinJuan Yao; Diana L Mandelker; Donavan T Cheng; Raghu Chandramohan; Abhinita S Mohanty; Ryan N Ptashkin; Gowtham Jayakumaran; Meera Prasad; Mustafa H Syed; Anoop Balakrishnan Rema; Zhen Y Liu; Khedoudja Nafa; Laetitia Borsu; Justyna Sadowska; Jacklyn Casanova; Ruben Bacares; Iwona J Kiecka; Anna Razumova; Julie B Son; Lisa Stewart; Tessara Baldi; Kerry A Mullaney; Hikmat Al-Ahmadie; Efsevia Vakiani; Adam A Abeshouse; Alexander V Penson; Philip Jonsson; Niedzica Camacho; Matthew T Chang; Helen H Won; Benjamin E Gross; Ritika Kundra; Zachary J Heins; Hsiao-Wei Chen; Sarah Phillips; Hongxin Zhang; Jiaojiao Wang; Angelica Ochoa; Jonathan Wills; Michael Eubank; Stacy B Thomas; Stuart M Gardos; Dalicia N Reales; Jesse Galle; Robert Durany; Roy Cambria; Wassim Abida; Andrea Cercek; Darren R Feldman; Mrinal M Gounder; A Ari Hakimi; James J Harding; Gopa Iyer; Yelena Y Janjigian; Emmet J Jordan; Ciara M Kelly; Maeve A Lowery; Luc G T Morris; Antonio M Omuro; Nitya Raj; Pedram Razavi; Alexander N Shoushtari; Neerav Shukla; Tara E Soumerai; Anna M Varghese; Rona Yaeger; Jonathan Coleman; Bernard Bochner; Gregory J Riely; Leonard B Saltz; Howard I Scher; Paul J Sabbatini; Mark E Robson; David S Klimstra; Barry S Taylor; Jose Baselga; Nikolaus Schultz; David M Hyman; Maria E Arcila; David B Solit; Marc Ladanyi; Michael F Berger Journal: Nat Med Date: 2017-05-08 Impact factor: 53.440
Authors: Viktor A Adalsteinsson; Gavin Ha; Samuel S Freeman; Atish D Choudhury; Daniel G Stover; Heather A Parsons; Gregory Gydush; Sarah C Reed; Denisse Rotem; Justin Rhoades; Denis Loginov; Dimitri Livitz; Daniel Rosebrock; Ignaty Leshchiner; Jaegil Kim; Chip Stewart; Mara Rosenberg; Joshua M Francis; Cheng-Zhong Zhang; Ofir Cohen; Coyin Oh; Huiming Ding; Paz Polak; Max Lloyd; Sairah Mahmud; Karla Helvie; Margaret S Merrill; Rebecca A Santiago; Edward P O'Connor; Seong H Jeong; Rachel Leeson; Rachel M Barry; Joseph F Kramkowski; Zhenwei Zhang; Laura Polacek; Jens G Lohr; Molly Schleicher; Emily Lipscomb; Andrea Saltzman; Nelly M Oliver; Lori Marini; Adrienne G Waks; Lauren C Harshman; Sara M Tolaney; Eliezer M Van Allen; Eric P Winer; Nancy U Lin; Mari Nakabayashi; Mary-Ellen Taplin; Cory M Johannessen; Levi A Garraway; Todd R Golub; Jesse S Boehm; Nikhil Wagle; Gad Getz; J Christopher Love; Matthew Meyerson Journal: Nat Commun Date: 2017-11-06 Impact factor: 14.919
Authors: Charu Aggarwal; Christian D Rolfo; Geoffrey R Oxnard; Jhanelle E Gray; Lynette M Sholl; David R Gandara Journal: Nat Rev Clin Oncol Date: 2020-09-11 Impact factor: 66.675
Authors: Stepan M Esagian; Georgia Ι Grigoriadou; Ilias P Nikas; Vasileios Boikou; Peter M Sadow; Jae-Kyung Won; Konstantinos P Economopoulos Journal: J Cancer Res Clin Oncol Date: 2020-05-27 Impact factor: 4.553
Authors: A Rose Brannon; Gowtham Jayakumaran; Monica Diosdado; Juber Patel; Anna Razumova; Yu Hu; Fanli Meng; Mohammad Haque; Justyna Sadowska; Brian J Murphy; Tessara Baldi; Ian Johnson; Ryan Ptashkin; Maysun Hasan; Preethi Srinivasan; Anoop Balakrishnan Rema; Ivelise Rijo; Aaron Agarunov; Helen Won; Dilmi Perera; David N Brown; Aliaksandra Samoila; Xiaohong Jing; Erika Gedvilaite; Julie L Yang; Dennis P Stephens; Jenna-Marie Dix; Nicole DeGroat; Khedoudja Nafa; Aijazuddin Syed; Alan Li; Emily S Lebow; Anita S Bowman; Donna C Ferguson; Ying Liu; Douglas A Mata; Rohit Sharma; Soo-Ryum Yang; Tejus Bale; Jamal K Benhamida; Jason C Chang; Snjezana Dogan; Meera R Hameed; Jaclyn F Hechtman; Christine Moung; Dara S Ross; Efsevia Vakiani; Chad M Vanderbilt; JinJuan Yao; Pedram Razavi; Lillian M Smyth; Sarat Chandarlapaty; Gopa Iyer; Wassim Abida; James J Harding; Benjamin Krantz; Eileen O'Reilly; Helena A Yu; Bob T Li; Charles M Rudin; Luis Diaz; David B Solit; Maria E Arcila; Marc Ladanyi; Brian Loomis; Dana Tsui; Michael F Berger; Ahmet Zehir; Ryma Benayed Journal: Nat Commun Date: 2021-06-18 Impact factor: 17.694